A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Status:
Completed
Trial end date:
2013-05-31
Target enrollment:
Participant gender:
Summary
This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte
(valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant
recipients. After transplantation, patients (aged 4 months to 16 years) will receive Valcyte
orally daily for up to 200 days post-transplant and will be followed for 52 weeks
post-transplantation.